P-0178 - Prognostic relevance of KRAS mutation in colorectal cancer patients without microsatellite instability
|Date||28 June 2014|
|Event||World GI 2014|
|Citation||Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165|
F. Khorshidi1, M. Yaghoob Taleghani2, A. Irani Shemirani3, A. Pourhosseingholi Mohammad4, E. Nazemalhosseini Mojarad2, H. Asadzadeh Aghdaei5, R. Zali Mohammad2
Background: Mutation of the KRAS (v-Kiras2 Kirsten rat sarcoma viral oncogene homologue) gene plays an important role in colorectal tumorigenesis. This study examined associations between KRAS gene mutations and clinicopathological and survival data in Iranian patients with microsatellite stable colorectal cancer (CRC).
CRC patients were recruited for the detection of KRAS gene mutations using polymerase chain reaction and DNA sequencing. Data on clinicopathological features and survival times were collected.
The study included 123 MSS CRC patients. The overall mutation frequency of the KRAS gene was 15.44% (19/123). KRAS gene mutations were significantly associated with tumour location and liver metastasis. Univariate analysis showed that stage III were associated with poor prognosis in CRC patients (P = 0.030), whereas multivariate analysis showed that KRAS gene mutation and stage III were independent factors for survival (P = 0.022, P = 0.012 respectively).
These findings suggest that a low frequency of KRAS gene mutations exists in Iranian patients with MSS CRC, and that such mutations are associated with poor survival, tumour location and liver metastasis in MSS CRC patients.